ALNY vs SYY Comparison

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Sysco is the largest foodservice distributor in the US, with an 18% share of the $377 billion vertical. The firm sells and distributes over 500,000 food and nonfood products to about 730,000 customer locations, primarily serving restaurants, which represented 60% of fiscal 2025 sales. The balance of sales stems from healthcare facilities (8%), education and government customers (8%), travel and leisure clients (7%), and other smaller end markets (17%), like cafeterias. By segment, Sysco earns the bulk of its revenue from its US foodservice operations (70%), followed by its international footprint (18%), SYGMA, which focuses on quick-service logistics (10%), and other (2%). The pending Jetro Restaurant Depot deal stands to add $16 billion in sales upon close, expected in fiscal 2027.